AXIM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXIM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AXIM Biotechnologies's Enterprise Value is $7.44 Mil. AXIM Biotechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.76 Mil. Therefore, AXIM Biotechnologies's EV-to-FCF for today is -9.77.
The historical rank and industry rank for AXIM Biotechnologies's EV-to-FCF or its related term are showing as below:
During the past 13 years, the highest EV-to-FCF of AXIM Biotechnologies was -0.98. The lowest was -82525.00. And the median was -9.96.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-13), AXIM Biotechnologies's stock price is $0.0021. AXIM Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.023. Therefore, AXIM Biotechnologies's PE Ratio (TTM) for today is At Loss.
The historical data trend for AXIM Biotechnologies's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-FCF | Get a 7-Day Free Trial | -5.62 | -18.14 | -26.04 | -5.33 | -10.10 |
AXIM Biotechnologies Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
EV-to-FCF | Get a 7-Day Free Trial | -9.04 | -7.84 | -10.10 | -4.99 | -12.72 |
For the Biotechnology subindustry, AXIM Biotechnologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's EV-to-FCF falls into.
AXIM Biotechnologies's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 7.443 | / | -0.762 | |
= | -9.77 |
AXIM Biotechnologies's current Enterprise Value is $7.44 Mil.
AXIM Biotechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies (OTCPK:AXIM) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AXIM Biotechnologies's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.0021 | / | -0.023 | |
= | At Loss |
AXIM Biotechnologies's share price for today is $0.0021.
AXIM Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.023.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of AXIM Biotechnologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Kurt Phinney | officer: Chief Operating Officer | 6914 MAGELLAN WAY, SARASOTA FL 34243 |
Peter O'rourke | director | C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001 |
Catalina Valencia | 10 percent owner | 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121 |
Glycodots, Llc | 10 percent owner | 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121 |
Juniper & Ivy Corp | 10 percent owner | 5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007 |
Huemoeller John Walter Ii | director | 305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960 |
Blake Schroeder | director | 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
Robert L Cunningham | director | 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
Timothy Richard Scott | director | 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
Robert Malasek | officer: CFO | PO BOX 235472, ENCINITAS CA 92023 |
Lekhram Changoer | 10 percent owner | 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
Medical Marijuana, Inc. | 10 percent owner | 12255 CROSTHWAITE CIRCLE, POWAY CA 92064 |
Van Damme Philip A | 10 percent owner | 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
Foundation Sanammad | 10 percent owner | 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
George Anastassov | 10 percent owner | 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-13-2022
By Value_Insider Value_Insider • 12-06-2022
By sperokesalga sperokesalga • 05-24-2023
By GuruFocusNews GuruFocusNews • 06-22-2022
By GuruFocusNews GuruFocusNews • 06-09-2022
By PurpleRose PurpleRose • 07-21-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
By PurpleRose PurpleRose • 07-13-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.